Insulin receptor substrate-2 (Irs2) in endothelial cells plays a crucial role in insulin secretion

Diabetes

Volumn 64, Issue 3, 2015, Pages 876-886

  Hashimoto, Shinji ^a   Kubota, Naoto ^a,b,c,d   Sato, Hiroyuki ^a   Sasaki, Motohiro ^a   Takamoto, Iseki ^a,b   Kubota, Tetsuya ^a,c,d,e   Nakaya, Keizo ^a   Noda, Mitsuhiko ^f   Ueki, Kohjiro ^a,b   Kadowaki, Takashi ^a,b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^d Institute of Physical and Chemical Research   (Japan)

^e TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^f NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ENALAPRIL MALEATE; GLUCAGON; GLUCOSE; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; LECTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INSULIN RECEPTOR SUBSTRATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DNA CONTENT; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; MALE; MEAN ARTERIAL PRESSURE; MICROVASCULATURE; MOUSE; NONHUMAN; PANCREAS BLOOD FLOW; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS PERFUSION; PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; SECRETION (PROCESS);

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ENALAPRIL; ENDOTHELIAL CELLS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; ISLETS OF LANGERHANS; MALE; MICE; MICE, KNOCKOUT;

EID: 84928207852     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0432     Document Type: Article

References (45)

1. Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984;26:44-49
2. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000;106:459-465
3. Reaven GM. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not? Diab Vasc Dis Res 2009;6:133-138
4. Movassat J, Bailbé D, Lubrano-Berthelier C, et al. Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion. Am J Physiol Endocrinol Metab 2008;294:E168-E175
5. Richards OC, Raines SM, Attie AD. The role of blood vessels, endothelial cells, and vascular pericytes in insulin secretion and peripheral insulin action. Endocr Rev 2010;31:343-363
6. Jansson L. The regulation of pancreatic islet blood flow. Diabetes Metab Rev 1994;10:407-416
7. Iwase M, Nakamura U, Uchizono Y, et al. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic capillary blood volume in the islet in rats. Eur J Pharmacol 2005;518:243-250
8. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-873
9. Haenni A, Andersson PE, Lind L, Berne C, Lithell H. Electrolyte changes and metabolic effects of lisinopril/bendrofluazide treatment. Results from a randomized, double-blind study with parallel groups. Am J Hypertens 1994;7: 615-622
10. Santoro D, Natali A, Palombo C, et al. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 1992;20:181-191
11. Huang Z, Jansson L, Sjöholm A. Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats. Clin Sci (Lond) 2007;112:69-76
12. Nyström T, Ortsäter H, Huang Z, et al. Inorganic nitrite stimulates pancreatic islet blood flow and insulin secretion. Free Radic Biol Med 2012;53:1017-1023
13. Kubota T, Kubota N, Moroi M, et al. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 2003;107:3073-3080
14. Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011;13:294-307
15. Kubota N, Terauchi Y, Tobe K, et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 2004;114:917-927
16. Terauchi Y, Takamoto I, Kubota N, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007;117:246-257
17. Olsson R, Carlsson PO. A low-oxygenated subpopulation of pancreatic islets constitutes a functional reserve of endocrine cells. Diabetes 2011;60:2068-2075
18. Miki T, Minami K, Shinozaki H, et al. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 2005;54:1056-1063
19. Jansson L, Hellerström C. A rapid method of visualizing the pancreatic islets for studies of islet capillary blood flow using non-radioactive microspheres. Acta Physiol Scand 1981;113:371-374
20. Sparrow RA, Beckingham IJ. Islet blood flow following insulin administration. J Anat 1989;163:75-81
21. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41:127-133
22. Ueki K, Okada T, Hu J, et al. Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet 2006;38:583-588
23. Goren HJ. Role of insulin in glucose-stimulated insulin secretion in beta cells. Curr Diabetes Rev 2005;1:309-330
24. Lammert E, Gu G, McLaughlin M, et al. Role of VEGF-A in vascularization of pancreatic islets. Curr Biol 2003;13:1070-1074
25. Annerén C, Welsh M, Jansson L. Glucose intolerance and reduced islet blood flow in transgenic mice expressing the FRK tyrosine kinase under the control of the rat insulin promoter. Am J Physiol Endocrinol Metab 2007;292: E1183-E1190
26. Dai C, Brissova M, Reinert RB, et al. Pancreatic islet vasculature adapts to insulin resistance through dilation and not angiogenesis. Diabetes 2013;62: 4144-4153
27. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002;20:2099-2110
28. Suzuki K, Nakagawa O, Aizawa Y. Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clin Exp Hypertens 2008;30:309-314
29. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23:463-473
30. Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999;48: 241-253
31. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensinconverting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003;91:30H-37H
32. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulindependent diabetes mellitus. Eur J Clin Invest 1987;17:448-454
33. Gans RO, Bilo HJ, Nauta JJ, Popp-Snijders C, Heine RJ, Donker AJ. The effect of angiotensin-I converting enzyme inhibition on insulin action in healthy volunteers. Eur J Clin Invest 1991;21:527-533
34. Torlone E, Rambotti AM, Perriello G, et al. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulindependent) diabetes mellitus and arterial hypertension. Diabetologia 1991;34: 119-125
35. Shieh SM, Sheu WH, Shen DD, et al. Improvement in metabolic risk factors for coronary heart disease associated with cilazapril treatment. Am J Hypertens 1992;5:506-510
36. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992;6:175-179
37. Morel Y, Gadient A, Keller U, Vadas L, Golay A. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 1995;26:306-311
38. Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am J Hypertens 1995;8:276-281
39. Suzuki M, Ikebuchi M, Yokota C, Shinozaki K, Harano Y. Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. Clin Exp Hypertens 1995;17:1257-1268
40. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999;12:298-303
41. Jacob S, Henriksen EJ, Fogt DL, Dietze GJ. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism 1996;45:535-541
42. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002;32(Suppl. 3):35-45
43. Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol 2007;580:31-37
44. Wang L, Leung PS. The role of renin-angiotensin system in cellular differentiation: implications in pancreatic islet cell development and islet transplantation. Mol Cell Endocrinol 2013;381:261-271
45. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004;53:989-997